Handelsbanken Fonder AB Buys 100,992 Shares of Kenvue Inc. $KVUE

Handelsbanken Fonder AB raised its stake in shares of Kenvue Inc. (NYSE:KVUE) by 10.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,034,460 shares of the company’s stock after purchasing an additional 100,992 shares during the period. Handelsbanken Fonder AB’s holdings in Kenvue were worth $17,844,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. Resona Asset Management Co. Ltd. raised its position in Kenvue by 1.4% during the 4th quarter. Resona Asset Management Co. Ltd. now owns 729,365 shares of the company’s stock worth $12,568,000 after purchasing an additional 10,004 shares during the last quarter. Aviance Capital Partners LLC raised its position in Kenvue by 91.8% during the 4th quarter. Aviance Capital Partners LLC now owns 26,461 shares of the company’s stock worth $456,000 after purchasing an additional 12,666 shares during the last quarter. ProShare Advisors LLC raised its position in Kenvue by 39.1% during the 4th quarter. ProShare Advisors LLC now owns 10,803,027 shares of the company’s stock worth $186,352,000 after purchasing an additional 3,036,196 shares during the last quarter. Intrua Financial LLC raised its position in Kenvue by 6.5% during the 4th quarter. Intrua Financial LLC now owns 19,825 shares of the company’s stock worth $342,000 after purchasing an additional 1,205 shares during the last quarter. Finally, GABELLI & Co INVESTMENT ADVISERS INC. bought a new position in Kenvue during the 4th quarter worth $7,227,000. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Performance

Shares of Kenvue stock opened at $17.33 on Thursday. The company has a current ratio of 0.98, a quick ratio of 0.70 and a debt-to-equity ratio of 0.67. The business has a 50-day moving average price of $17.42 and a two-hundred day moving average price of $17.39. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $24.35. The company has a market cap of $33.27 billion, a P/E ratio of 20.38, a PEG ratio of 1.30 and a beta of 0.55.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The firm had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $3.84 billion. During the same period last year, the business posted $0.24 EPS. The business’s revenue was up 4.5% compared to the same quarter last year. As a group, analysts anticipate that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th will be paid a $0.2075 dividend. The ex-dividend date is Wednesday, May 13th. This represents a $0.83 annualized dividend and a dividend yield of 4.8%. Kenvue’s dividend payout ratio (DPR) is currently 97.65%.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on KVUE shares. Barclays lowered their target price on Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 14th. Canaccord Genuity Group increased their price target on Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a report on Wednesday, February 18th. Zacks Research upgraded Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. Jefferies Financial Group downgraded Kenvue from a “buy” rating to a “hold” rating and decreased their price target for the stock from $23.00 to $18.00 in a report on Friday, January 30th. Finally, Argus upgraded Kenvue to a “hold” rating in a report on Friday, March 6th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Kenvue presently has a consensus rating of “Hold” and an average target price of $19.33.

Insider Activity at Kenvue

In other news, General Counsel Matthew Orlando sold 38,491 shares of the firm’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.59% of the stock is currently owned by corporate insiders.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.